Trinity Biotech (TRIB) Total Current Liabilities (2009 - 2025)

Trinity Biotech has reported Total Current Liabilities for 17 years, with the latest figure at $141.2 million in Q4 2025.

• Quarterly Total Current Liabilities rose 339.97% year-over-year to $141.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $141.2 million (up 339.97% YoY) and the FY2025 annual result came in at $141.2 million, up 339.97% from the prior year.
• Total Current Liabilities rose to $141.2 million in Q4 2025 per TRIB's latest filing, from $31.5 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $141.2 million in Q4 2025 and troughed at $12.7 million in Q3 2023.
• A 5-year average of $41.3 million and a median of $24.3 million in 2024 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2021 and 2022: Total Current Liabilities jumped 364.27% in 2021, then plunged 86.86% in 2022.
• Over 5 years, Total Current Liabilities stood at $100.5 million in 2021, then tumbled by 82.75% to $17.3 million in 2022, then slipped by 13.29% to $15.0 million in 2023, then surged by 113.47% to $32.1 million in 2024, then soared by 339.97% to $141.2 million in 2025.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $141.2 million, $31.5 million, and $32.1 million for Q4 2025, Q2 2025, and Q4 2024 respectively.